Author

Yang Cao

Singapore Clinical Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Developmental Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Assay:Hi-C· 1 Organism:human· 1 Research Focus:phylogenetics / evolution· 1 Assay:proteomics· 1

Frequent Co-Authors

Aleksandra Jartseva· 1 shared Andreas LackneriD· 1 shared Bertille MontibusiD· 1 shared Bong Hwa Gan· 1 shared Brian HendrichiD· 1 shared Darren Wan Teck Lim· 1 shared David LandoiD· 1 shared Dhananjay Umrani· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperDevelopmental Biology

Aleksandra Jartseva

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Enhancer-promoter interactions are reconfigured through the formation of long-range multiway chromatin hubs as mouse ES cells exit pluripotency

David Lando, Xiaoyan Ma, Yang Cao, Aleksandra Jartseva, Tim J. Stevens, Wayne Boucher, Nicola Reynolds, Bertille Montibus, Dominic Hall, Andreas Lackner, Ramy Ragheb, Martin Leeb, Brian Hendrich, Ernest D. Laue

The paper studies 3D genome structure changes in single mouse ES cells exiting pluripotency, finding reorganization of enhancer-promoter interactions through multiway chromatin hubs.

Molecular Cell · Mar 14, 2024Peer-reviewedDevelopmental Biology

Pharmacodynamic evaluation of AUM001/tinodasertib, an oral inhibitor of mitogen-activated protein kinase (MAPK)-interacting protein kinase 1, 2 (MNK1/2) in preclinical models and tissues from a Phase 1 clinical study

Bong Hwa Gan, Lay Hoon Lee, Reika Takeda, Maryam Yasin, Vincenzo Teneggi, Kantharaj Ethirajulu, Pauline Yeo, Dhananjay Umrani, Vishal Pendharkar, Darren Wan Teck Lim, Greg Li, Qingshu Lu, Yang Cao, Ranjani Nellore, Stephanie Blanchard, , Veronica Novotny-Diermayr

This paper evaluates the pharmacodynamic effects of AUM001/tinodasertib in preclinical models and human tissues from a Phase 1 study, showing dose-dependent inhibition of eIF4E phosphorylation in tumors and PBMCs.

Journal of Cancer Science and Clinical Therapeutics · Jan 1, 2024Peer-reviewedCancer Biology